Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction.
The aim of this study was to investigate the behavior of plasma endothelin-1 (ET-1) in 23 patients with acute myocardial infarction, complicated and uncomplicated by left ventricular failure, and treated with and without thrombolytic agents. ET-1 was measured on admission; on days 2, 3, and 5; and again on discharge. In addition, on discharge, ET-1 was correlated with left ventricular systolic function. Left ventricular failure was present, on admission, in 14 patients, whereas the other nine did not have any hemodynamic impairment. On discharge, no patients had left ventricular failure, but 11 had moderate to severe left ventricular systolic dysfunction, defined as left ventricular ejection fraction (LVEF) < 40%. Fourteen subjects, matched for age and sex, served as a control group. Compared with the control range, ET-1 was highly elevated on the first day, in both uncomplicated (p < 0.01) and complicated patients (p < 0.001). Then it decreased rapidly in the uncomplicated group, reaching the control range within day 5, whereas in the complicated group it remained significantly elevated in comparison with both the control subjects and the uncomplicated patients, until discharge. ET-1 was not correlated with the peak of creatine-kinase MB isoenzyme in any group. In seven patients submitted to thrombolytic treatment ET-1 was always significantly lower than in the nonthrombolyzed patients (p < 0.05), but the pattern of variation across time was no different. On discharge, the difference in plasma ET-1 between patients with LVEF < 40% and the control group was significant (p < 0.001), as was the difference between patients with and without moderate to severe systolic dysfunction (p < 0.01). ET-1 was closely and inversely correlated with LVEF when patients were considered as a whole (p < 0.001). These results suggest that the ET-1 increase in the early phase of myocardial infarction could be due to an ischemic process, to stress reaction, and to cardiac hemodynamic impairment, and therefore, ET-1 may be a good marker of disease. In the following phase the ET-1, being correlated with LVEF, could be a reliable index of systolic function.
Battistelli
S
S
Istituto di Semeiotica Medica e Geriatria, University of Siena, Italy. battistelli@unisi.it
Billi
M
M
Manasse
G
G
Vittoria
A
A
Roviello
F
F
Forconi
S
S
D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D003402:Creatine Kinase / Q000097:blood; D004562:Electrocardiography; D019332:Endothelin-1 / Q000097:blood*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000209:etiology; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D011379:Prognosis; D011863:Radioimmunoassay; D013318:Stroke Volume; D015912:Thrombolytic Therapy; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000150:complications
D015415:Biomarkers; D019332:Endothelin-1; D005343:Fibrinolytic Agents; D007527:Isoenzymes; D003402:Creatine Kinase